[The predictive value of the GRF-stimulation test].
Andler. W W; Eiden. S S
Key Findings
- GRF‑1‑29 stimulation test has high specificity for children with normal pituitary function.
- The test has poor sensitivity for detecting true growth‑hormone deficiency.
- Many children with hypothalamic disorders still respond to GRF, leading to false‑positive results.
Practical Outcomes
- For biohackers, this means GRF‑1‑29 is not a useful self‑test for assessing growth‑hormone status in adults or for performance enhancement. It’s mainly a diagnostic tool for pediatric endocrinology and should not be relied upon for personal health optimization.
Summary
The study looked at using a short version of growth‑hormone‑releasing factor (GRF‑1‑29) to test if kids have growth‑hormone problems. It found the test is good at confirming normal pituitary function but often gives false positives for hypothalamic issues, so it isn’t reliable for diagnosing growth‑hormone deficiency.
Abstract
48 patients between one and seventeen years of age were stimulated with GRF (1-29) NH2. Seventeen of them showed a constitutional delay in growth and puberty, twenty-three suffered from growth-hormone deficiency (GHD) and eight had a suspected GHD as a result of pharmacological tests. Although the results demonstrate a high specificity for GH release in children with constitutional delay of growth and patients with functioning hypophyseal gland, the sensitivity for diagnosis of GHD was poor. The majority of GHD patients suffer from hypothalamic disorders and therefore respond to GRF. In conclusion, the GRF-stimulation test may be sufficient for differentiation of hypophyseal or hypothalamic disorders. However, GRF-stimulation test shows too many false positive results in hypothalamic growth disorders and therefore is not recommended for diagnosis of GHD.
Study Information
pubmed
1990
10.1055/s-2007-1025510